<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206881</url>
  </required_header>
  <id_info>
    <org_study_id>PO5903, EudraCT 2008-007951-29</org_study_id>
    <nct_id>NCT01206881</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of neoadjuvant treatment with
      pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide +/- trastuzumab followed by
      docetaxel in patients with locally advanced, inflammatory breast cancer or with a primary
      tumor &gt; 5 cm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locally advanced or inflammatory breast cancer have a very bad prognosis.
      Several studies have shown that patients who receive a pathological complete response have
      the best prognosis. Neoadjuvant chemotherapy including anthracyclines and taxanes has become
      established as a standard option in the multidisciplinary management of this group of
      patients. In HER2 positive patients, chemotherapy in combination with trastuzumab is
      therapeutically attractive. Recent studies have also demonstrated that evaluation with PET-CT
      scan can be used to stratify treatment and monitor early response to neoadjuvant therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluation of treatment efficacy every 2.cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathological response rate, response rate as defined by PET-CT scan, mammography and ultrasound, evaluation of toxicity of the combination regimen</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin</intervention_name>
    <description>35 mg/m2, IV, day 1 every 21 days, 4 cycles</description>
    <other_name>cyclophosphamide, 4 cycles</other_name>
    <other_name>docetaxel, 4 cycles</other_name>
    <other_name>trastuzumab, 8 cycles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically proven breast cancer

          -  inflammatory, locally advanced breast cancer or a tumor &gt; 5 cm

          -  ECOG performance status &lt; 2

          -  LVEF &gt; 50% measured by MUGA (HER2 positive patients)

          -  adequate bone marrow, liver and renal function

          -  written informed consent must be obtained

        Exclusion Criteria:

          -  another malignancy within 5 years prior to study entry

          -  concurrent treatment with an investigational agent

          -  other disease or condition that contraindicates participation in the study

          -  pregnant or lactating females
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malgorzata K Tuxen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital, Department of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla B Tange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soeren Cold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne B SÃ¸ndergaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Petersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inger Hoejris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anni Eskild-Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Malgorzata K. Tuxen, MD, phd, consultant</name_title>
    <organization>Department of Oncology, Herlev Hospital</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>liposomal doxorubicin</keyword>
  <keyword>PET scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

